Albeit there is a number of established predictive and prognostic factors, most of which are also therapeutic targets (e.g. estrogen, progesterone receptor (ER, PR) or HER-2), the management options are still primarily based on the cancer’s basic clinicopathological features, such as tumor size, lymph node stage, histological grade, type, and lymphovascular invasion [4–7]. This evidence concerns the gene PGR and neoplasm.